AU2004286144A1 - Method for producing gene transferred dendritic cells - Google Patents

Method for producing gene transferred dendritic cells Download PDF

Info

Publication number
AU2004286144A1
AU2004286144A1 AU2004286144A AU2004286144A AU2004286144A1 AU 2004286144 A1 AU2004286144 A1 AU 2004286144A1 AU 2004286144 A AU2004286144 A AU 2004286144A AU 2004286144 A AU2004286144 A AU 2004286144A AU 2004286144 A1 AU2004286144 A1 AU 2004286144A1
Authority
AU
Australia
Prior art keywords
cells
dendritic cells
gene
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004286144A
Other languages
English (en)
Other versions
AU2004286144A2 (en
Inventor
Mamoru Hasegawa
Shinji Okano
Satoko Shibata
Katsuo Sueishi
Yoshikazu Yonemitsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of AU2004286144A1 publication Critical patent/AU2004286144A1/en
Publication of AU2004286144A2 publication Critical patent/AU2004286144A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004286144A 2003-11-04 2004-10-29 Method for producing gene transferred dendritic cells Abandoned AU2004286144A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003374808 2003-11-04
JP2003-374808 2003-11-04
JP2004-187028 2004-06-24
JP2004187028 2004-06-24
PCT/JP2004/016089 WO2005042737A1 (ja) 2003-11-04 2004-10-29 遺伝子導入された樹状細胞の製造方法

Publications (2)

Publication Number Publication Date
AU2004286144A1 true AU2004286144A1 (en) 2005-05-12
AU2004286144A2 AU2004286144A2 (en) 2005-05-12

Family

ID=34554806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004286144A Abandoned AU2004286144A1 (en) 2003-11-04 2004-10-29 Method for producing gene transferred dendritic cells

Country Status (8)

Country Link
US (1) US20070269414A1 (cg-RX-API-DMAC7.html)
EP (1) EP1690937B1 (cg-RX-API-DMAC7.html)
JP (2) JPWO2005042737A1 (cg-RX-API-DMAC7.html)
KR (1) KR101279748B1 (cg-RX-API-DMAC7.html)
CN (1) CN1902312B (cg-RX-API-DMAC7.html)
AU (1) AU2004286144A1 (cg-RX-API-DMAC7.html)
CA (1) CA2544786A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005042737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
AU2001244675A1 (en) 2000-03-30 2001-10-08 Dnavec Research Inc. Aids virus vaccine with the use of sendai virus vector
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US20060104950A1 (en) * 2002-10-24 2006-05-18 Shinji Okano Methods of Tranducing genes into T cells
WO2005001082A1 (ja) * 2003-06-30 2005-01-06 Dnavec Research Inc. 高変異領域が改変された遺伝子を搭載するマイナス鎖rnaウイルスベクター
CA2544786A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
WO2005067981A1 (ja) * 2004-01-13 2005-07-28 Dnavec Research Inc. 免疫刺激性サイトカインをコードするマイナス鎖rnaウイルスベクターを用いる腫瘍の遺伝子治療
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
AU2005257107A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
CN101405389A (zh) * 2006-01-17 2009-04-08 生物载体株式会社 新型蛋白质表达系统
JPWO2008136438A1 (ja) * 2007-04-27 2010-07-29 国立大学法人九州大学 遺伝子治療用ウイルスベクター
CN101755045B (zh) 2007-05-17 2014-02-12 生物载体株式会社 树突状细胞的制备方法
WO2009013018A2 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
WO2009028945A2 (en) * 2007-08-30 2009-03-05 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Pathways involved in arteriogenesis and uses thereof
US20120015040A1 (en) * 2008-03-03 2012-01-19 University Of Toledo Dendritic Cell Precursor Populations, Dendritic Cell Populations Derived Therefrom and Uses Thereof
US8741639B2 (en) 2008-11-14 2014-06-03 Dnavec Corporation Method for producing dendritic cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2020237315A1 (en) * 2019-05-31 2020-12-03 Telethon Kids Institute Immunogenic compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
JPH01285498A (ja) 1988-05-11 1989-11-16 Mitsubishi Heavy Ind Ltd 宇宙用パネル展開装置
TW232710B (cg-RX-API-DMAC7.html) 1991-09-13 1994-10-21 American Cyanamid Co
JPH05192160A (ja) 1992-01-20 1993-08-03 Banyu Pharmaceut Co Ltd Ｃ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡ及びポリペプチド
EP0619840A1 (en) 1992-10-06 1994-10-19 Akzo Nobel N.V. Pseudorabies virus vaccine
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE69435155D1 (de) * 1993-04-30 2008-12-04 Wellstat Biologics Corp Zusuammensetzungen zur Behandlung von Krebs mittels Viren
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
KR100552387B1 (ko) * 1995-10-31 2006-04-21 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 rna 바이러스 벡터
DK0863202T3 (da) * 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
AU1733697A (en) 1996-02-29 1997-09-16 Takara Shuzo Co., Ltd. Method of purifying and removing viruses
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
CA2368948C (en) 1999-05-18 2013-12-24 Dnavec Research Inc. Envelope gene-deficient virus vector of paramyxoviridae
WO2000070055A1 (en) 1999-05-18 2000-11-23 Dnavec Research Inc. Rnp originating in paramyxovirus
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
US20020123479A1 (en) * 1999-12-08 2002-09-05 Song Elizabeth S. Immunostimulation mediated by gene-modified dendritic cells
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
AU2001244675A1 (en) * 2000-03-30 2001-10-08 Dnavec Research Inc. Aids virus vaccine with the use of sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US20050013810A1 (en) * 2001-05-08 2005-01-20 Waller Edmund K Regulating immune response using dendritic cells
JP2005505261A (ja) * 2001-07-05 2005-02-24 ファイロジックス・インコーポレーテッド 樹状細胞単離法
CN1636229B (zh) * 2001-09-06 2012-12-19 西北生物治疗药物公司 引发单核树突细胞和t细胞th-1应答的组合物和方法
KR20040039366A (ko) * 2001-09-18 2004-05-10 가부시키가이샤 디나벡크 겐큐쇼 입자 형성능이 저하된 （－）가닥 ｒｎａ 바이러스 벡터의 검사방법 및 제조방법
EP1438399A4 (en) * 2001-09-28 2005-09-14 Univ North Carolina PARAMYXOVIRES AS VECTORS FOR GENTRANSFER IN LUNG CELLS
WO2003029475A1 (fr) * 2001-09-28 2003-04-10 Dnavec Research Inc. Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
WO2003102183A1 (en) * 2002-06-03 2003-12-11 Dnavec Research Inc. Pramyxovirus vectors encoding antibody and utilization thereof
AU2002951082A0 (en) * 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents
US20060104950A1 (en) * 2002-10-24 2006-05-18 Shinji Okano Methods of Tranducing genes into T cells
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
CA2544786A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
WO2005067981A1 (ja) * 2004-01-13 2005-07-28 Dnavec Research Inc. 免疫刺激性サイトカインをコードするマイナス鎖rnaウイルスベクターを用いる腫瘍の遺伝子治療
EP2434020B1 (en) * 2004-01-22 2014-11-05 Dnavec Research Inc. Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter
CA2560046A1 (en) * 2004-03-16 2005-09-22 Dnavec Research Inc. Methods for suppressing tumor proliferation
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
AU2005257107A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
EP1891215B1 (en) * 2005-04-20 2009-10-28 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
EP2034014A1 (en) * 2006-05-31 2009-03-11 Dnavec Corporation Therapeutic agent for alzheimer's disease
CN101755045B (zh) * 2007-05-17 2014-02-12 生物载体株式会社 树突状细胞的制备方法

Also Published As

Publication number Publication date
KR101279748B1 (ko) 2013-07-04
EP1690937A4 (en) 2007-01-03
EP1690937B1 (en) 2012-10-17
CN1902312B (zh) 2011-02-23
JP2012065652A (ja) 2012-04-05
KR20060125783A (ko) 2006-12-06
WO2005042737A1 (ja) 2005-05-12
CN1902312A (zh) 2007-01-24
EP1690937A1 (en) 2006-08-16
CA2544786A1 (en) 2005-05-12
AU2004286144A2 (en) 2005-05-12
US20070269414A1 (en) 2007-11-22
JPWO2005042737A1 (ja) 2007-05-10
HK1103418A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
EP1690937B1 (en) Method of constructing transgenic dendritic cell
KR101270839B1 (ko) Ｒｎａ 바이러스가 도입된 수상세포를 포함하는 항암제
EP1561819A1 (en) Method of transferring gene into t cells
US7521043B2 (en) Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
EP2143794A1 (en) Viral vector for gene therapy
HK1089208A (en) Method of constructing transgenic dendritic cell
HK1103418B (en) Method for producing gene transferred dendritic cells
HK1078108A (en) Method of transferring gene into t cells
HK1088036A (en) Methods of transducing genes into t cells
HK1094874A (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
HK1106793A (en) Anticancer agent containing minus-strand rna virus

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 MAY 2006

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2006

MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination